Compare Amphastar Pharmaceuticals Inc (AMPH) vs Aterian Inc (ATER) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Aterian (ATER) trades at $1.15, down 3.36% with a bullish technical signal despite negative profitability. Revenue has declined from $221M in 2022 to $69M in 2025, with net losses narrowing but persisting. The company is pursuing an asset sale, with proxy advisors recommending stockholders vote for transactions expected to return $0.85-$1.14 per share. Analyst sentiment is split evenly between Buy and Hold ratings.

The outlook hinges on the successful asset sale providing shareholder returns, but fundamental challenges remain with sustained losses and cash burn. Investment opportunity exists in the potential special dividend, while risks include ongoing operational losses and competitive pressures in consumer products.